Find Academic Supervisors

Matthias MannView profile

Professor

• Mass Spectrometry
• Proteomics
• Systems Biology
• +6 more

Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.

• Neural circuit mechanisms
• Adaptive learning
• State-dependent decision-making
• +4 more

Dr. Sabine Krabbe is a Group Leader at the German Center for Neurodegenerative Diseases (DZNE) in Bonn, Germany, where she leads research on neural circuit mechanisms underlying adaptive learning and state-dependent decision-making. Her work integrates neuroscience, molecular biology, and behavioral approaches to understand how internal states influence behavior and how these processes are disrupted in neurological disorders. Dr. Krabbe's research focuses on the interactions between midbrain circuits of the substantia nigra and ventral tegmental area with their output structures such as the striatum and amygdala. She investigates how these networks integrate internal states with environmental cues to produce appropriate behavioral responses. Her laboratory employs state-of-the-art techniques including deep-brain calcium imaging at single-cell resolution in mice, opto- and pharmacogenetic manipulations, anatomical tracings, and molecular approaches to characterize neural circuit elements in detail. Her recent publications reveal significant insights into amygdala interneuron plasticity during fear learning, brain-wide representational drift in memory consolidation, and the molecular mechanisms underlying Parkinson's disease progression. Her work demonstrates how activity patterns within specific neural circuits change in early stages of neurodegenerative diseases and how this dysfunction contributes to cognitive deficits and emotional disturbances. Dr. Krabbe is actively involved in the neuroscience community, organizing the BonnBrain Conference 2026 and sharing research through social media platforms. She has established herself as an emerging leader in the field of systems neuroscience with a particular focus on the neural basis of emotional states and decision-making processes.

Omer BayraktarView profile

Researcher

• Neural Diversity
• Spatial Transcriptomics
• Glia Biology
• +3 more

Omer Bayraktar is a Group Leader at the Wellcome Sanger Institute , leading research in the Cellular Genomics Programme. His work focuses on decoding human brain cellular diversity using spatial transcriptomics , imaging , and functional screening to study neural complexity in health and disease. Bayraktar's educational background includes a PhD from HHMI under Chris Doe, investigating neural diversity development in Drosophila , followed by postdoctoral work at University of California, San Francisco and University of Cambridge as a Life Sciences Research Foundation Fellow. He developed a spatial transcriptomic pipeline during his postdoc to analyze astrocyte heterogeneity in the cerebral cortex. His research explores neural cell type mapping , glial-neuronal interactions , and cellular pathways in neurodevelopmental disorders . Recent publications emphasize 3D tissue mapping , multi-omic integration , and computational tools like Cell2fate and WebAtlas. His work bridges neurogenetics and computational biology to advance understanding of human tissue ecosystems. Bayraktar's lab collaborates with the Human Cell Atlas initiative and develops technologies such as automated histology pipelines and highly-multiplexed smFISH for molecular cell typing. His team also investigates glia-based therapies and astrocyte functional heterogeneity in neurodevelopmental contexts. Key scientific contributions include: Discovering astrocyte layer patterns independent of neuronal laminae Developing cell2location for spatial cell mapping Characterizing Drosophila neural stem cell models with human relevance Notable awards include the Life Sciences Research Foundation Fellowship during his postdoctoral training. His current group includes a PhD student , Senior Data Scientists , and Bioinformaticians .

• Behavioral Ecology
• Evolutionary Biology
• Population Ecology
• +11 more

Prof. Dr. Oliver Krüger is a behavioral ecologist and evolutionary biologist at Bielefeld University 's Faculty of Biology , where he leads the Department of Animal Behaviour since 2013. His research spans avian and marine mammal systems, focusing on life history strategies, parasite-host interactions, and environmental adaptation. Education: Biology studies at Bielefeld University (1994-1996) MSc in Oxford (1996-1997) PhD at Bielefeld University with Fritz Trillmich and Jan Lindström (1998-2000) Research Themes: Behavioral ecology, evolutionary biology, and population dynamics across tropical and temperate ecosystems. Key projects include NC³ (Niche Choice/Construction) and studies on Galápagos sea lions, common buzzards, and pinniped species. Scientific Leadership: Spokesperson, SFB TRR 212 "NC³" (2018-2025) Advisory Board member: German Ornithologists Union, IUCN SSC pinniped group, German Primate Centre Peer review roles: Humboldt Foundation, DFG, HFSP, NSF Awards: Leopoldina Prize (2001) Niko Tinbergen Award (2008) DFG Heisenberg Professorship (2010-2015)

Nikolaus RajewskyView profile

Professor

• RNA Biology
• Gene Regulation
• Single-Cell Transcriptomics
• +6 more

Nikolaus Rajewsky is a leading Professor at the Max Delbrück Center for Molecular Medicine (MDC) and Charité – Universitätsmedizin Berlin , where he founded and directs the Berlin Institute for Medical Systems Biology (BIMSB) . His lab integrates experimental (biochemistry, molecular biology) and computational (bioinformatics, physics) approaches to study RNA regulation in gene expression , with applications to developmental biology, regeneration, neurodegenerative diseases, and cancer . Using model systems like C. elegans , planaria, and human brain organoids, his team pioneers cutting-edge methods such as MirDeep , DistMap , and FLAM-seq for RNA analysis. His research focuses on single-cell transcriptomics , spatial RNA sequencing , and circular RNA (circRNA) regulation , revealing novel roles for circRNAs like CDR1as in neuropsychiatric disorders. Recent work includes 3D tumor microenvironment mapping and computational modeling of RNA metabolism in diseases. Scientific Awards : Gottfried Wilhelm Leibniz Prize (2012) EMBO Membership (2010) Honorary PhD, Sapienza University of Rome (2014) Berlin Science Award (2009) His team's recent articles highlight breakthroughs in 3D spatial transcriptomics , circRNA degradation mechanisms , and mitochondrial disease modeling using human brain organoids. The lab actively collaborates with clinical partners across Charité and European institutions, driving the LifeTime initiative for cell-based interceptive medicine.

Jörg HackermüllerView profile

Professor

• Bioinformatics
• Omics Data Analysis
• Toxicology
• +3 more

Prof. Dr. Jörg Hackermüller is a computational biologist with expertise in Omics data integration Toxicology Environmental risk assessment Non-coding RNA biology . He serves as Head of the Department of Computational Biology and Chemistry at the Helmholtz Centre for Environmental Research (UFZ) since 2024 and holds a Professorship at the Faculty of Mathematics and Computer Science at Leipzig University since 2021. His research focuses on Developing AI methods for chemical toxicity prediction Multi-omics integration for mechanistic toxicology Data standardization in environmental monitoring Non-coding RNAs as biomarkers in disease and toxicity and has produced 15+ recent publications spanning tools like multiGSEA and deepFPlearn+ . He collaborates with teams across UFZ Leipzig University Novartis Fraunhofer Institute and leads projects like InCeTo and SafePol , integrating exposome research with systems biology.

• Tissue Regeneration
• Stem Cell Biology
• Comparative Regeneration
• +3 more

Prof. Kerstin Bartscherer leads the Animal Physiology department at Osnabrück University, focusing on mechanisms of tissue regeneration in organisms such as planarian flatworms and spiny mice (Acomys). Her research emphasizes scar-free regeneration, cardiac repair, and evolutionary insights into regenerative capabilities. She co-leads the EU-funded Regenerate-IT doctoral network and recently organized the successful 25th German Society for Developmental Biology conference. Her team includes PhD students Saman Ghodsi and Robert Kopplin, and collaborates with junior research group leader Dr. Lena Tveriakhina. Key projects explore stem cell regulation, comparative regeneration strategies, and in vitro models using iPSC-derived cells. Education & Affiliations: No explicit educational background provided in texts, but affiliated with Osnabrück University's Biology faculty. Research Interests: Integrates molecular biology, comparative physiology, and evolutionary approaches to identify barriers to regeneration in mammals versus regenerative species. Prioritizes translational applications for human regenerative medicine. Publications highlight groundbreaking work on spiny mouse ear regeneration mechanisms and cardiac repair processes. Current initiatives include cross-disciplinary training via the Regenerate-IT network, fostering the next generation of regeneration biologists. Grants & Projects: EU MSCA-DN Regenerate-IT funding, institutional support for comparative regeneration studies. Labs/Teams: Animal Physiology lab team with specialized focus areas in stem cell dynamics, transcriptomics, and in vivo/in vitro model systems.

Kirsten JungView profile

Professor

• Bacterial Signal Transduction
• Stress Response Mechanisms
• Membrane Protein Structure-Function Analysis
• +3 more

Prof. Dr. Kirsten Jung is a faculty member at the Department of Microbiology , Faculty of Biology , Ludwig Maximilian University of Munich . Her research focuses on bacterial signal transduction, stress response mechanisms, and systems biology approaches to understand microbial regulatory networks. Key research areas include stress-dependent gene expression in bacterial populations Structural and functional analysis of membrane-integrated receptors Metabolism-based chemical communication in bacteria Integration of experimental and computational systems biology Recent publications highlight her lab's work on Escherichia coli epitranscriptomic modifications under heat stress, m 5 C rRNA dynamics, and the role of RNA methylation in host-pathogen interactions. Collaborative studies address bacterial acid stress responses and their implications for antibiotic tolerance. Her interdisciplinary work bridges microbiology with ecological studies, as evidenced by research on biodiversity conservation in forest and urban ecosystems. Publications also demonstrate expertise in advanced imaging techniques (e.g., arterial spin labeling for glioma analysis) and bioinformatics approaches. Current advisees include Gloria Gessinger and Tania P. Gonzalez-Terrazas . She can be contacted at jung@lmu.de .

• Muscle Metabolism
• Aging Research
• mTORC1 Signaling
• +6 more

Dr. Stephanie de Alcantara Fernandes is a Minerva Fast Track Group Leader at the Max Planck Institute for Biology of Ageing in Cologne, Germany, where she leads research on muscle metabolism and aging. Her laboratory investigates how spatial and functional regulation of mTORC1 signaling influences skeletal muscle health, growth, and regeneration throughout the lifespan, with implications for understanding and promoting healthy aging. Dr. Fernandes completed her academic training through a distinguished path: PhD in Biology (Summa cum laude, with distinction), University of Cologne/Max Planck Institute for Biology of Ageing (2017-2023) Master of Science in Genetics, University of São Paulo (2015-2017) Bachelor of Science in Biological Sciences, University of São Paulo (2009-2014) Exchange year at University of Birmingham, UK (2013) Her research focuses on skeletal muscle biology, particularly the balance between anabolic and catabolic processes that maintain muscle health. Dr. Fernandes investigates how mTORC1 (mechanistic Target of Rapamycin Complex 1), a central signaling hub, is spatially organized within cells to selectively regulate specific cellular functions in response to different nutrient sources. Her work reveals that mTORC1 is not simply "on or off" but can be finely tuned to control distinct processes in different cellular compartments, particularly in skeletal muscle cells. A key aspect of her research examines how these regulatory mechanisms change with age, contributing to age-related muscle loss (sarcopenia). By understanding the molecular basis of muscle maintenance and regeneration, her laboratory aims to identify targets for interventions that could promote healthier aging and prevent age-related decline in muscle function. Analysis of Dr. Fernandes' publication record shows a clear trajectory of increasingly independent research focused on mTORC1 signaling, nutrient sensing, and their roles in aging and muscle biology. Her most recent work demonstrates sophisticated understanding of mTORC1's spatial regulation, revealing how different pools of mTORC1 respond to distinct amino acid sources to control specific cellular processes. This research bridges fundamental cell biology with translational applications for aging-related conditions. Dr. Fernandes has received numerous prestigious awards recognizing her scientific excellence: Minerva Fast Track Fellowship (2025) - Group Leader Position for Outstanding Female Scientists from Max Planck Society Graduate School for Biological Sciences (GSfBS) doctoral award for 2023 (2025) World Muscle Society Fellowship (2016) Cologne Graduate School of Ageing Research fellowship (2017-2020) Master's scholarship from São Paulo Research Foundation (2015-2017) Science Without Borders Scholarship from Brazilian Council for Scientific and Technological Development (2013) As a newly appointed Group Leader through the Minerva Fast Track program, Dr. Fernandes is establishing her independent research program with substantial institutional support. Her laboratory combines advanced techniques including high-throughput omics approaches (proteomics, metabolomics), molecular biology, biochemistry, cell biology, and super-resolution microscopy. She utilizes multiple model systems including mouse models, skeletal muscle cell lines, and iPSC-derived skeletal muscle cells to identify evolutionarily conserved mechanisms relevant to human health. Dr. Fernandes leads the Minerva Fast Track Group at the Max Planck Institute for Biology of Ageing, which focuses specifically on "Muscle metabolism and aging." Her team investigates how selective mTORC1 signaling is coordinated between different skeletal muscle cell types and how it changes with age, with the ultimate goal of understanding how muscle health can be maintained throughout life.

Karol Nowicki-OsuchView profile

Research Fellow

• Cancer Biology
• Molecular Oncology
• Gastrointestinal Cancers
• +3 more

Dr. Karol Nowicki-Osuch is a Group Leader at the German Cancer Research Center (DKFZ) , leading a research group focused on tumorigenesis and molecular cancer prevention. His work emphasizes understanding early stages of gastrointestinal tumor development using multimodal techniques like single-cell RNA sequencing, organoid models, and spatial transcriptomics. Key research areas include the molecular mechanisms underlying Barrett's esophagus, gastric intestinal metaplasia, and the transition to adenocarcinoma. Collaborations span institutions in Germany, Poland, the UK, and the US. His team investigates how normal epithelial cells lose molecular identity and progress to precancerous states. Notable achievements include demonstrating that esophageal adenocarcinoma originates from gastric tissue and identifying novel mutational signatures using the mutREAD method. Current projects aim to develop early cancer detection strategies and in vivo models of tumor progression. Dr. Nowicki-Osuch supervises PhD students and employs cutting-edge technologies such as spatial transcriptomics and organoid platforms. His lab integrates computational biology with experimental approaches to address gaps in understanding clonal evolution and somatic mutations in gastroesophageal cancers.

• Artificial Intelligence
• Probabilistic Graphical Models
• Deep Generative Models
• +4 more

Ewa Szczurek is a Professor at the University of Warsaw's Faculty of Mathematics, Informatics and Mechanics and Co-director of the Institute for AI for Health, leading joint labs at Helmholtz Munich and the University of Warsaw. Education: Master degree in Computer Science from Uppsala University, Sweden (2005) Master degree in Computer Science from University of Warsaw, Poland (2006) Doctoral degree from Max Planck Institute for Molecular Genetics, Berlin (2011) Postdoctoral fellowship at ETH Zurich, Switzerland (2011) Habilitation at University of Warsaw, Poland (2020) Visiting associate professor at Northwestern University, USA (2023) Research Focus: Her work centers on probabilistic graphical models and deep generative models applied to computational medicine, with emphasis on oncology (tumor microenvironment modeling and evolution), pulmonology, and AI-driven antimicrobial peptide design to combat antibiotic resistance. She develops specialized deep learning frameworks for spatial transcriptomics analysis, tumor evolution reconstruction, and synthetic antimicrobial compound generation. Publication Trends: Recent publications (2022-2023) demonstrate consistent innovation in AI-driven biomedical solutions, bridging machine learning with oncology and infectious disease research. Her work shows increasing focus on generative models for drug design and spatial data analysis, with strong industry-academia collaborations (e.g., Merck, IMMUcan consortium). Awards: ERC Consolidator Grant (2023) for DOG-AMP project Scientific and didactic award from Rector of University of Warsaw ETH Zurich and IMPRS fellowship awards Grants & Leadership: Leads the ERC Consolidator Grant project DOG-AMP for antimicrobial peptide design. Serves as Associate Editor for Genome Biology and participates in program committees for ISMB and RECOMB-CCB conferences. Collaborates with international consortia including IMMUcan and Merck's Oncology Bioinformatics department. Labs & Networks: Co-directs AI for Health Institute with joint labs at Helmholtz Munich and University of Warsaw. Active in ELLIS (pan-European AI network) and Polish Bioinformatics Society, driving interdisciplinary research at the AI-medicine interface.

Marios GeorgakisView profile

Researcher

• Cardiovascular Disease
• Stroke
• Atherosclerosis
• +8 more

Marios Georgakis is a clinician-scientist and Junior Group Leader at the Institute for Stroke and Dementia Research (ISD) at LMU Munich. He also holds a Visiting Scientist position at the Broad Institute of MIT and Harvard. His research focuses on leveraging multi-omics data and causal inference methods (e.g., Mendelian randomization) to discover drug targets for atherosclerosis, develop personalized risk stratification tools for cerebrovascular disease, and identify in vivo biomarkers of disease activity. His work bridges human genetics, molecular biology, and clinical translation. Education : MD and PhD (Epidemiology) from the National and Kapodistrian University of Athens; doctoral studies in Systemic Neurosciences at LMU Munich. Honors : Emmy Noether Award (DFG), CHARGE Consortium Early Career Achievement Award, Hertie Network Fellowship, and multiple scholarships/fellowships. Research Themes : Drug target discovery for cardiovascular disease via multiomics integration Molecular phenotyping of atherosclerosis using single-cell RNA-seq and spatial transcriptomics Development of AI-driven tools for vascular imaging and aging Genetic studies of inflammation, cytokines, and stroke subtypes Causal inference in vascular risk prediction and post-stroke outcomes Recent Article Trends : His team's publications (2024-2020) emphasize: Proteogenomic and genetic studies of atherosclerosis Cytokine signaling pathways (e.g., IL-6, CCL2/CCR2) Polygenic and genomic risk scores for stroke Multi-omics biomarkers in cerebrovascular disease Clinical translation of Mendelian randomization findings Meta-analyses of population-based data Scientific Awards : Emmy Noether Group Leader Award (DFG, 2023) CHARGE Consortium Early Career Achievement (2023) Hertie Network Fellowship (2023) Walter-Benjamin Postdoctoral Fellowship (2021-2022) Team Leadership : Georgakis mentors multiple PhD students and postdocs in his lab. His group collaborates with vascular surgeons, neurologists, and computational biologists. Current projects include the AtherOMICS biobank and AI-driven vascular phenotyping tools.

Marios GeorgakisView profile

Researcher

• Biomedical Neuroscience
• Cerebrovascular Disease
• Stroke
• +7 more

Dr. Marios Georgakis is a Clinician-Scientist and Junior Group Leader at the Institute for Stroke and Dementia Research (ISD) at Ludwig-Maximilians-Universität München (LMU Munich). He also serves as a Visiting Scientist at the Broad Institute of MIT and Harvard and is completing his clinical residency in Neurology at LMU University Hospital. As Principal Investigator of the Georgakis Lab, he leads a research team focused on developing precision medicine approaches for cerebrovascular diseases. Education: Medical studies (M.D.): Medical School, National and Kapodistrian University of Athens, Greece (2009-2015) Master studies (M.Sc.): Molecular Physiology (Neurosciences), National and Kapodistrian University of Athens, Greece (2015-2017) Doctoral studies (D.Sc.) in Epidemiology, National and Kapodistrian University of Athens, Greece (2015-2019) Doctoral studies (Ph.D.) in Graduate School of Systemic Neurosciences (GSN), LMU Munich, Germany (2017-2020) Dr. Georgakis' research focuses on leveraging big data from epidemiological studies and human biobanks to develop precise and personalized preventive and therapeutic strategies for cerebrovascular diseases. His work spans biomedical neuroscience with particular emphasis on cerebrovascular disease, stroke, atherosclerosis, cerebral small vessel disease, multi-omics, data science, epidemiology, and population genetics. He employs innovative bioinformatic tools including genome-wide association studies, Mendelian randomization, multi-omics integration, single-cell transcriptomics, spatial transcriptomics, and machine learning to discover causal mechanisms, identify therapeutic targets, develop risk stratification tools, and create accurate biomarkers for cerebrovascular diseases. His laboratory has established the AtherOMICS biobank for human atherosclerotic plaque samples and developed computational pipelines for big data analyses. Recent publication trends show a strong focus on genetic architecture of stroke, inflammatory pathways in cerebrovascular disease, and development of polygenic risk scores for clinical application. Scientific Awards: Emmy Noether Independent Group Leader Award, German Research Foundation (DFG), 2023 Early Career Achievement Award, CHARGE Consortium, 2023 Fellow of the Hertie Network of Excellence in Clinical Neuroscience, 2023 Clinician-Scientist Fellow of the Excellence Munich Cluster for Systems Neurology (SyNergy), 2023 Walter-Benjamin Fellowship for postdoctoral research by German Research Foundation (DFG), 2021-2022 Dr. Georgakis actively mentors a diverse team of 12 current students and postdocs including PhD students, MD students, and clinician scientists, with several alumni who have completed their training in his lab. His research is supported by multiple grants including the Emmy Noether program from the German Research Foundation, focusing on multi-omics characterization of immune mechanisms driving human atheroprogression, dissecting cerebrovascular atherosclerosis with population genetics, and developing personalized biomarkers using deep learning. The Georgakis Lab operates two main research platforms: the AtherOMICS Biobank for human atherosclerotic plaque samples and the Big Data Lab for computational analyses. These platforms enable his team to conduct deep phenotyping of human atherosclerosis, develop in vivo diagnostics, discover therapeutic targets, and create personalized diagnostic and risk prediction tools for cardiovascular diseases.

Mathias MunschauerView profile

Researcher

• Molecular Virology
• RNA Biology
• Host-Pathogen Interactions
• +7 more

Mathias Munschauer leads the Department of Molecular Virology at Heidelberg University's Faculty of Medicine, within the Center for Infectious Diseases. His research group focuses on unraveling RNA regulatory mechanisms that govern viral infection outcomes, with emphasis on HCV, HBV, and Dengue virus. His research interests lie at the intersection of RNA biology and virology, particularly in understanding how viral RNA molecules interact with host cell components. The lab employs cutting-edge methodologies including RAP-MS and SHIFTR for RNA interactomics, integrated with functional genomics, single-cell transcriptomics, and AI-driven analysis of high-dimensional data. This systems-level approach enables the identification of host factors and regulatory pathways critical for viral replication and immune evasion. The recent publications highlight a strong trend toward spatially and temporally resolved analysis of RNA-protein interactions across diverse RNA viruses. There is a consistent focus on developing and applying innovative technologies to map host-virus interfaces, with applications in identifying antiviral targets and understanding infection mechanisms. The work spans molecular, cellular, and systems biology, with increasing integration of computational and machine learning approaches. Systems virology RNA-protein interactomics Host-pathogen interactions CRISPR screening Single-cell analysis Antiviral strategies Dr. Munschauer mentors a research team and contributes to the doctoral program in Infectious Diseases. His lab develops and shares novel reagents and methods, fostering collaborative science. While specific grants are not listed, the technological sophistication suggests substantial funding support. The lab operates within a vibrant research environment alongside other virology groups such as AG Bartenschlager and AG Ruggieri. The Munschauer Lab is part of a larger virology and infectious disease research ecosystem at Heidelberg University, collaborating across disciplines to advance understanding of viral pathogenesis. The team actively develops and applies innovative tools for RNA-centric discovery, positioning the group at the forefront of molecular virology.

Jane A. McKeatingView profile

Professor

• Virology
• Hepatology
• Molecular Biology
• +3 more

Jane A. McKeating is a Professor of Molecular Virology at the University of Oxford's Nuffield Department of Medicine. She holds the Hans Fischer Senior Fellowship at the Technical University of Munich's Institute for Advanced Study (TUM-IAS) since 2015. Her research focuses on viral infections, particularly hepatitis B (HBV) and C (HCV), exploring how hypoxia and circadian rhythms regulate viral replication and pathogenesis. She has held roles at institutions including the University of Birmingham (2005–2017) and Rockefeller University (2000–2005). Education: BSc in Biological Sciences, University of Warwick (1982) PhD in Virology, Royal Free Hospital School of Medicine, University College London (1987) Research Interests: Her work investigates how low oxygen (hypoxia) and circadian signaling pathways influence viral replication and tropism, particularly in liver and immune cells. Recent studies include SARS-CoV-2 regulation by hypoxia-inducible factors (HIFs) and circadian clock components like BMAL1. She also examines therapies targeting these pathways to combat viral infections. Publications: Her recent work spans hepatitis virus biology, antiviral screening tools, and circadian regulation of viral infections. Key themes include viral entry mechanisms, immune evasion, and drug development. Awards: 2015 Founders Award, University of Birmingham 2006 Royal Society Wolfson Merit Award 1995 Fleming Award, Society of General Microbiology Lab & Collaborations: Her research group at Oxford focuses on viral-host interactions, with collaborations on spatial transcriptomics of HBV/HDV/HIV co-infections and antiviral drug screening platforms.